Positive in vitro (human lymphocyte micronucleus, mouse lymphoma); negative in vivo rat micronucleus and comet assays
“Gepotidacin was positive in an in vitro micronucleus test in human peripheral blood lymphocytes and in an L5178Y mouse lymphoma assay, consistent with the known in vitro clastogenic effects of topoisomerase inhibitors in in vitro mammalian cell assays. Gepotidacin was negative in an in vivo micronucleus test or Comet assay in rat.”
Mouse and rat EFD: decreased fetal weight and late resorptions below clinical exposure; mouse pre/postnatal study: no adverse effects
“In embryo‑fetal development studies in mice and rats, decreased fetal weights and increased fetal mortality (late resorptions) were observed at exposures less than the maximum recommended human dose (MRHD). In a mouse pre- and postnatal development study, there were no adverse developmental effects at exposures approximately equal to the MRHD”
Dog: no arrhythmias or QTc prolongation; increased heart rate, arterial pressure, contractility and cardiac load
“No arrhythmias or heart-rate corrected QT interval (QTc) prolongation were detected in an oral safety pharmacology study in dogs; however, gepotidacin was associated with increases in heart rate, mean arterial pressure, cardiac contractility, and cardiac load.”
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative